Amylyx Pharmaceuticals, Inc. (AMLX) › Cash & EquivalentsAmylyx Pharmaceuticals, Inc. (AMLX) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2021-12-31: $50.19M2022-12-31: $62.53M2023-12-31: $170.20M2024-12-31: $77.39M2025-12-31: $226.65M$226.65M2021-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$226.65M+192.9%2026-03-03Balance as of period end2024-12-31$77.39M-54.5%2026-03-03Balance as of period end2023-12-31$170.20M+172.2%2025-03-04Balance as of period end2022-12-31$62.53M+24.6%2024-02-22Balance as of period end2021-12-31$50.19M—2023-03-13Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)